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Physiologically based kinetic (PBK)
modeling
Plant food supplements (PFS)
Risk assessmenta b s t r a c t
Basil-containing plant food supplements (PFS) can contain estragole which can be metabolised into a
genotoxic and carcinogenic 10-sulfoxymetabolite. This study describes the inhibition of sulfotransferase
(SULT)-mediated bioactivation of estragole by compounds present in basil-containing PFS. Results reveal
that PFS consisting of powdered basil material contain other compounds with considerable in vitro SULT-
inhibiting activity, whereas the presence of such compounds in PFS consisting of basil essential oil was
limited. The inhibitor in powdered basil PFS was identiﬁed as nevadensin. Physiologically based kinetic
(PBK) modeling was performed to elucidate if the observed inhibitory effects can occur in vivo. Subse-
quently, risk assessment was performed using the Margin of Exposure (MOE) approach. Results suggest
that the consequences of the in vivo matrix-derived combination effect are signiﬁcant when estragole
would be tested in rodent bioassays with nevadensin at ratios detected in PFS, thereby increasing MOE
values. However, matrix-derived combination effects may be limited at lower dose levels, indicating that
the importance of matrix-derived combination effects for risk assessment of individual compounds
should be done on a case-by-case basis considering dose-dependent effects. Furthermore, this study illus-
trates how PBK modeling can be used in risk assessment of PFS, contributing to further reduction in the
use of experimental animals.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Plant food supplements (PFS) are widely marketed throughout
Europe where they are sold in pharmacies, drug stores, health-food
shops, supermarkets and via the internet. Despite the fact that the
use of botanical products is suggested to be beneﬁcial for overall
health, the use of some PFS that are available on the market might
raise concerns as several botanicals are known to contain toxiccompounds (EFSA, 2012). Examples of naturally present botanical
compounds of concern include the group of alkenylbenzenes
(EFSA, 2012; van den Berg et al., 2011a, 2011b). In fact, it was re-
cently demonstrated that some – though not all – PFS derived from
basil, fennel, nutmeg, sassafras or calamus contain relatively high
levels of the alkenylbenzenes estragole, methyleugenol, safrole
and/or b-asarone (van den Berg et al., 2011b). Based on the Margin
of Exposure (MOE) approach it was even concluded that the use of
such products, at dose levels recommended by the respective
manufacturers, may lead to a daily intake of these genotoxic
carcinogens comparable to dose levels causing malignant tumours
in rodents, indicating a priority for risk management and a poten-
tial risk for human health (van den Berg et al., 2011b). It is impor-
tant to note that the available tumour data for these food-borne
alkenylbenzenes, which were used to estimate the MOE values,
were obtained from long-term rodent studies performed with pure
compounds dosed in the absence of a botanical matrix (Miller
et al., 1983). It can be argued whether such data represent an ade-
quate basis for the risk assessment for these botanical products
(Rietjens et al., 2008).
The genotoxic and carcinogenic activity of alkenylbenzenes has
been ascribed to their bioactivation by cytochromes P450, leading
to the formation of 10-hydroxymetabolites, and the subsequent
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(SULTs), generating unstable DNA reactive 10-sulfoxymetabolites
(Fig. 1) (Anthony et al., 1987; Drinkwater et al., 1976; Miller
et al., 1983; Sangster et al., 1987; Solheim and Scheline, 1973;
Wiseman et al., 1987). Interestingly, a previous study (Jeurissen
et al., 2008) showed that a methanolic basil extract caused a reduc-
tion in the level of DNA-adduct formation in incubations with DNA
and rat or human liver S9 as well as in human hepatoma HepG2
cells exposed to 10-hydroxyestragole, demonstrating the impor-
tance of the botanical matrix. The major compound in the metha-
nolic basil extract responsible for this in vitro inhibition of theFig. 1. Metabolic pathways of estragole. Arrows in bold indicate the bioaSULT-mediated bioactivation of estragole was found to be the
ﬂavonoid nevadensin (Alhusainy et al., 2010). Recently, it was
demonstrated that nevadensin is also able to signiﬁcantly inhibit
the SULT-mediated bioactivation of estragole in vivo, resulting in
reduced levels of estragole DNA-adducts in the livers of rats ex-
posed simultaneously to estragole and nevadensin as compared
to the estragole DNA-adduct levels in the livers of rats exposed
to estragole alone (Alhusainy et al., 2013).
Although a methanolic basil extract could thus markedly inhibit
the metabolic bioactivation of estragole, compositional changes
might occur when processing and manufacturing PFS. As a result,ctivation to 10-sulfoxyestragole and the formation of DNA-adducts.
34 S.J.P.L. van den Berg et al. / Food and Chemical Toxicology 62 (2013) 32–40the level of SULT-inhibition can be different for botanicals used as
herbs and spices compared to processed PFS prepared from the
same botanical. Therefore, the aims of the present study were (1)
to examine the effect on the bioactivation of estragole by com-
pounds present in PFS consisting of powdered basil material or
its essential oils for which we previously demonstrated a potential
risk for human health (van den Berg et al., 2011b), (2) to identify
the most potent SULT inhibitor(s) in these PFS, (3) to perform phys-
iologically based kinetic (PBK) modeling to elucidate if the ob-
served inhibitory effects can occur in vivo and (4) to perform an
updated risk assessment for the basil-containing PFS based on
the MOE approach taking this matrix-derived combination effect
into account.2. Materials and methods
2.1. PFS and chemicals
Five basil-containing PFS were selected for which a risk assessment was previ-
ously made based on the MOE approach, indicating that use of all these basil-con-
taining PFS results in MOE values in the range of 1–1000 pointing at a high priority
for risk management actions and a potential risk for human health (van den Berg
et al., 2011b). Two of the selected PFS consisted of powdered basil material and
three of the selected PFS were prepared from the essential oil of basil. Characteris-
tics of the selected PFS are presented in Table 1. Basil-containing PFS were pur-
chased via the internet.
Apigenin, 7-hydroxycoumarin (7HC), 7-hydroxycoumarin sulfate (7HCS), tris-
(hydroxymethyl)aminomethane, 30-phosphoadenosine-50-phosphosulfate (PAPS)
and pentachlorophenol (PCP) were purchased from Sigma–Aldrich (Steinheim, Ger-
many). Nevadensin was from Sinova Inc. (Bethesda, USA). Pooled liver S9 frommale
Sprague–Dawley rats and mixed gender pooled human liver S9 were supplied by BD
Gentest (Woburn, United States). Acetic acid was obtained from VWR International
(Darmstadt, Germany) and dimethyl sulfoxide (DMSO) was from Acros Organics
(Geel, Belgium). Methanol (ULC/MS grade) and acetonitrile (ULC/MS grade) were
purchased from Biosolve (Valkenswaard, The Netherlands). Ultrapure water was
obtained from a Barnstead Nanopure Type I ultrapure water system.
2.2. Preparation of methanolic PFS extracts
The selected PFS consisting of powdered basil material were extracted as de-
scribed previously (Alhusainy et al., 2010; Jeurissen et al., 2008). In short, 5 g of
powdered PFS material was extracted with a mixture of methanol, water and acetic
acid (ratio 80:19:1) by stirring the powdered PFS material twice for 2 h at room
temperature, each time using 100 ml of the extraction mixture. After ﬁltration of
the extract solution through a folded ﬁlter (Schleicher & Schuell), the ﬁltrates of
each PFS were pooled and evaporated to dryness using a rotary evaporator (Hei-
dolph LABOROTA 4000 efﬁcient, Metrohm, USA). The extraction yields were found
to range between 21.6% and 23.8%. The dried extracts were subsequently dissolvedTable 1
Levels of estragole and nevadensin in basil-containing PFS included in the present study.
Sample
no.
Characteristics of PFS included in the present study
(van den Berg et al., 2011b)
1 Supplement consisting of powdered plant material, preparation method
unknown. Recommended daily dose equals 1–3 capsules, consistent with
230–690 mg total PFS per day
2 Supplement consisting of powdered plant material, preparation method
unknown. Recommended daily dose equals 4–6 capsules, consistent with
1580–2370 mg total PFS per day
3 Supplement consisting of 100% essential oil including 12.5 mg Ocimum
basilicum essential oil per 100 mg supplement (i.e. 32.5 mg per capsule).
Recommended daily dose equals 6 capsules, consistent with 1560 mg total
PFS per day
4 Supplement consisting of 100% essential oil including 3.7 mg Ocimum
basilicum essential oil per 100 mg supplement (i.e. 10 mg per capsule).
Recommended daily dose equals 1–4 capsules, consistent with 270–
1080 mg total PFS per day
5 Supplement consisting of 100% essential oil including 10.6 mg Ocimum
basilicum essential oil per 100 mg supplement (i.e. 30 mg per capsule).
Recommended daily dose equals 2–3 capsules, consistent with 565–
848 mg total PFS per day
ND: not detected, NC: not calculated.in methanol to obtain concentrations of 2, 5, and 20 mg/ml. PFS consisting of basil
essential oil were directly dissolved in methanol to obtain a concentration of 20 mg/
ml followed by sonication (Bandelin Sonorex RK 100) for 10 min at room tempera-
ture. Thereafter, dilution series were prepared in methanol to make aliquots of 2
and 5 mg/ml. All stocks were ﬁltered using a 0.2 lM cellulose acetate ﬁlter mem-
brane (VWR international) and stored at 20 C until use in the SULT assay.
2.3. SULT assay
The inhibition of SULT activity by the different methanolic basil-containing PFS
extracts was measured as described by Alhusainy et al. (2010). Since the sulfonated
10-hydroxymetabolite of estragole is unstable in an aqueous environment, hamper-
ing its direct detection by means of HPLC analysis, 7-hydroxycoumarin (7HC) was
used as a substrate as previously described (Alhusainy et al., 2010, 2012). Incuba-
tions were performed in a total volume of 100 ll with 0.1 M Tris–HCl (pH 7.4) con-
taining (ﬁnal concentrations) 0.4 mg/ml commercially obtained pooled liver S9
from male Sprague–Dawley rats or mixed gender pooled human liver S9, 0.1 mM
30-phosphoadenosine-50-phosphosulfate (PAPS) and 10, 25 or 100 lg/ml of a meth-
anolic PFS extract (added from a 200 times concentrated stock in methanol). Prior
to the addition of 25 lM 7HC (added from a 200 times concentrated stock solution
in DMSO), samples were pre-incubated for 1 min at 37 C. Reaction mixtures were
incubated for 10 min at 37 C and terminated by adding 25 ll ice-cold acetonitrile.
Incubations performed in the absence of PFS extract or in the presence of 25 lM of
the known SULT inhibitor pentachlorophenol (PCP) (added from a 200 times con-
centrated stock solution in DMSO) were used as controls. In addition, blank incuba-
tions were performed in the absence of the co-factor PAPS or S9 liver homogenates.
In all incubations, the total amount of methanol and/or DMSO was kept below 1%
(v/v). All samples were centrifuged at 5 C for 5 min at 16,000 g and the supernatant
was stored at 20 C until HPLC analysis. Experiments were performed in triplicate.
2.4. HPLC analysis and quantiﬁcation of 7HCS
For quantiﬁcation of 7HCS, 50 ll of each sample obtained in the SULT assay was
subjected to HPLC analysis as described previously (Alhusainy et al., 2010, 2012).
Chromatographic analysis was performed using a Waters 2695 separation module
liquid chromatography system, connected to a 2996 photodiode array detector
and an Alltima C18 5 lm column, 150 mm  4.6 mm (Grace Alltech, Breda, The
Netherlands). The gradient was made with ultrapure water containing 0.1% (v/v)
acetic acid and acetonitrile. The ﬂow rate was 1 ml/min and a gradient was applied
from 0% acetonitrile to 20% acetonitrile in 2 min, increased to 21% acetonitrile over
10 min and further increased to 100% acetonitrile in 2 min at which it was kept for
1 min. Starting conditions were reached in the next 2 min and retained for another
10 min. Under the conditions applied, 7HCS eluted at 6.2 min.
2.5. Fractionation of methanolic basil-containing PFS extracts
All methanolic basil-containing PFS extracts were subjected to fractionation
based on the method described previously (Alhusainy et al., 2010). In short, 50 ll
of a concentrated PFS extract (i.e. 150 mg/ml) dissolved in methanol were injected
into a Waters 600 controller liquid chromatography system connected to a Waters
996 photodiode array detector. Chromatographic separation was performed usingAverage level of estragole ± StDEV








1.21 ± 0.11 0.17 ± 0.04 0.14
0.20 ± 0.01 0.24 ± 0.06 1.19
183.85 ± 2.24 ND NC
32.71 ± 1.46 ND NC
241.56 ± 62.02 ND NC
S.J.P.L. van den Berg et al. / Food and Chemical Toxicology 62 (2013) 32–40 35an Alltima C18 5 lm column 150 mm  4.6 mm (Grace Alltech, Breda, The Nether-
lands). The gradient was made with ultrapure water containing 0.1% (v/v) acetic
acid and methanol. The ﬂow rate was 1 ml/min. The mobile phase started with
0% methanol and was increased to 100% methanol within 60 min at which it was
kept for 10 min. Starting conditions were reached in 10 min and retained in the
next 10 min. In total, 60 fractions with a 1 min interval were collected into Eppen-
dorf tubes. Subsequently, the methanolic solvent present in the collected fractions
was evaporated under a stream of gaseous nitrogen and the residual water was re-
moved by freeze drying using a Christ Alpha RVC freeze dryer at 0.8–1.2 mbar. For
each basil-containing PFS, fractionation was repeated ﬁve times and the dried frac-
tions obtained of each replicate were pooled by reconstituting them in 50 ll meth-
anol. All fractions were tested in the SULT activity assay for their SULT-inhibitory
potential.
Identiﬁcation and quantiﬁcation of the compounds present in the most potent
fractions were accomplished by comparison of their retention times and UV spectra
to the retention times and UV spectra of commercially available reference
compounds.2.6. UPLC analysis and quantitative detection of nevadensin in PFS consisting of basil
For quantiﬁcation of nevadensin, the major SULT-inhibiting constituent in the
methanolic basil-containing PFS extracts prepared in this study (see results sec-
tion), 3.5 ll of each methanolic extract was subjected to UPLC analysis (n = 3). UPLC
analysis was performed on a Waters ACQUITY UPLC H-Class system connected to an
ACQUITY UPLC photodiode array detector and a quaternary solvent manager. Chro-
matographic separation was achieved using an ACQUITY UPLC BEH C18 1.7 lm col-
umn, 2.1  50 mm. The column was kept at 30 C and the sample manager was set
at 10 C. The gradient was made with nanopure water containing 0.1% (v/v) TFA and
acetonitrile. The ﬂow rate was 0.6 ml/min and a gradient was applied from 0% ace-
tonitrile to 20% acetonitrile in 0.2 min, increased to 79% acetonitrile over 1.8 min
and further increased to 100% acetonitrile in 0.2 min at which it was kept for
0.6 min. Starting conditions were reached in the next 0.2 min and retained for an-
other 1.2 min. The levels of nevadensin were quantiﬁed by comparing the peak
areas to those in the calibration curve of nevadensin deﬁned using a commercially
available reference compound.2.7. PBK modeling, BMDL10 analysis and updated risk assessment using the MOE
approach
An updated risk assessment of basil-containing PFS was made including the ma-
trix-derived combination effect of nevadensin on the bioactivation of estragole. The
reduction in the formation of estragole DNA-adducts (N2-(trans-isoestragol-30-y1)-
20-deoxyguanosine (E-30-N2-dGuo)) in the liver of rat following the combined expo-
sure to estragole and nevadensin was predicted based on the PBK models previ-
ously developed for the bioactivation and detoxiﬁcation of estragole (Punt et al.,
2009) including a sub-model describing the absorption, distribution, metabolism
and excretion of nevadensin (Alhusainy et al., 2013). The binary estragole–nevaden-
sin PBK model used in this study was previously validated based on an in vivo study
in which rats were exposed to estragole and nevadensin showing that the PBK mod-
el based predictions adequately match the measured DNA-adduct levels in the liver
of rats (Alhusainy et al., 2013). In the present study, the estragole–nevadensin mod-
el (Alhusainy et al., 2013) was run for a period of 24 h using the estragole dose lev-
els administered to mice (Miller et al., 1983) and a relative ratio of estragole and the
SULT inhibitor nevadensin reﬂecting their occurrence in the speciﬁc PFS.Fig. 2. Inhibition of the SULT-mediated conversion of 7HC to 7HCS by methanolic extracts
bars) or human liver (grey bars) S9 homogenates, 7HC as a substrate and PAPS as a co
methanolic basil-containing PFS extracts or 25 lM PCP (positive control). Data are pr
methanolic PFS extract (i.e. control MeOH). An asterix (*) indicates a signiﬁcant decreaseBased on the outcomes of the PBK model, the incidence of hepatomas as re-
ported by Miller et al. (1983) was reﬁned assuming a linear relationship between
the reduced formation of E-30-N2-dGuo DNA-adducts and the reduction in the hep-
atoma incidence. In a next step, reﬁned BMDL10 (i.e. the lower conﬁdence limit of
the benchmark dose resulting in a 10% extra cancer incidence) values were calcu-
lated by performing a BMD (Benchmark Dose) analysis of the newly reﬁned hepa-
toma incidences using EPA BMD software (version 2.1.2) as previously described
(van den Berg et al., 2011b). MOE values were calculated by dividing the reﬁned
BMDL10 values by the estimated daily intake of estragole resulting from the use
of each speciﬁc basil-containing PFS of interest (Table 1) (van den Berg et al.,
2011b).3. Results
3.1. Inhibition of SULT activity in rat and human liver S9 homogenates
by methanolic extracts of basil-containing PFS
The inhibition of SULT activity by several methanolic basil-con-
taining PFS extracts in incubations with rat and human liver S9 is
shown in Fig. 2. All tested methanolic extracts were found to inhi-
bit the metabolic conversion of 7HC to 7HCS in a dose-dependent
manner. The extracts prepared from PFS consisting of powdered
basil material (i.e. PFS1 and PFS2) were found to exert the most po-
tent SULT-inhibiting effects. In fact, in human liver S9 homoge-
nates, PFS2 completely blocked the formation of 7HCS at all
concentrations tested (i.e. ﬁnal concentrations of 10, 25 and
100 lg/ml) comparable to the effect observed when incubations
were performed using 25 lM of the known SULT inhibitor PCP. In
contrast, extracts that were prepared from PFS consisting of the
essential oil of basil (i.e. PFS3, PFS4 and PFS5) resulted in only a
moderate level of SULT-inhibition (Fig. 2). Chromatographic analy-
sis of incubations performed in the absence of the cofactor PAPS or
S9 liver homogenates demonstrated that under these conditions
7HCS was not formed.
3.2. Fractionation of methanolic extracts of basil-containing PFS
The methanolic extracts of basil-containing PFS were subjected
to fractionation using HPLC. Fig. 3 displays the inhibition of the
SULT-catalysed conversion of 7HC to 7HCS by all fractions obtained
upon fractionation of methanolic extracts of the powdered basil-
containing PFS (i.e. PFS1 and PFS2) (Fig. 3A and B) or from PFS con-
taining basil-derived essential oil (i.e. PFS3, PFS4 and PFS5)
(Fig. 3C–E). A potent SULT-inhibiting effect was shown for several
fractions of the methanolic extracts prepared from PFS consisting
of powdered basil material (Fig. 3A and B). Fraction 51 was found
to exert the highest level of SULT-inhibiting activity for PFS1 and
PFS2 (Fig. 3A and B). In fact, the formation of 7HCS was completelyof several basil-containing PFS. Incubations were performed using pooled rat (black
factor in the presence or absence of ﬁnal concentrations of 10, 25 or 100 lg/ml of
esented as a percentage of the amount of 7HCS formed in incubations without a
in the formation of 7HCS compared to incubations without SULT inhibitor (p < 0.05).
Fig. 3. Inhibition of the SULT-mediated conversion of 7HC to 7HCS by several basil-containing PFS fractions collected by HPLC. Incubations were performed using pooled rat
liver S9 homogenates, 7HC as a substrate and PAPS as a cofactor in the presence of fractions of (A) basil-containing PFS1, (B) basil-containing PFS2, (C) basil-containing PFS3,
(D) basil-containing PFS4 or (E) basil-containing PFS5. Data are presented as a percentage of the amount of 7HCS formed in incubations without SULT inhibitor (i.e. control
MeOH).
36 S.J.P.L. van den Berg et al. / Food and Chemical Toxicology 62 (2013) 32–40blocked in the presence of fraction 51. Fraction 50 of PFS1 also re-
sulted in complete inhibition of SULT activity, whereas for PFS2
this fraction resulted in an almost complete SULT-inhibition of
92.9%. In addition, for both methanolic PFS extracts from powdered
basil material, fraction 45 and 46 were found to contain potentSULT inhibitors resulting in a level of SULT-inhibition of 92.9–
96.1%. Chromatographic analysis of fraction 50 and 51 demon-
strated the presence of only one major compound in both fractions
which was identiﬁed as nevadensin based on comparison of the
retention time and UV spectra of these fractions to those of a
S.J.P.L. van den Berg et al. / Food and Chemical Toxicology 62 (2013) 32–40 37commercially available standard of nevadensin. Apigenin was
identiﬁed in fraction 46 of both PFS consisting of powdered basil
material (i.e. PFS1 and PFS2), although chromatographic analysis
of this fraction also revealed the presence of other minor
constituents.
In comparison to the methanolic extracts prepared from PFS
consisting of powdered basil material, the level of SULT-inhibition
by fractions of methanolic extracts from PFS consisting of basil
essential oil was found to be limited amounting to 39.4% or less
(Fig. 3C, D and E). Moreover, there was no analogy between the
three fractionation patterns with regard to the fractions showing
the most potent SULT-inhibiting effect.3.3. PBK prediction of the effect of nevadensin on in vivo estragole
DNA-adduct formation
PBK modeling was performed to predict the in vivo effect of the
combined exposure to estragole and nevadensin on E-30-N2-dGuo
formation in rat liver. The binary estragole–nevadensin PBK model
used for these analyses was previously validated based on an
in vivo study in which DNA-adducts were quantiﬁed in the liver
of rats simultaneously exposed to estragole and nevadensin
(Alhusainy et al., 2013).
DNA-adduct formation was modeled using the binary
estragole–nevadensin PBKmodel (Alhusainy et al., 2013) at estragole
dose levels used in the estragole rodent bioassay (Miller et al.,
1983) on which our previous risk assessment of the basil-contain-
ing PFS was based (van den Berg et al., 2011b). Table 2 shows that
the level of estragole DNA-adduct formation in rat liver at dose lev-
els of 54 and 107 mg/kg bw/day estragole are predicted by the PBK
model to equal 1983 adducts in 108 nt and 4114 adducts in 108 nt
in the absence of nevadensin. In the presence of nevadensin, at a
ratio between estragole and nevadensin reﬂecting their levels in
PFS1, a reduction in the formation of estragole DNA-adducts by
65% (i.e. 688 adducts in 108 nt) and 66% (i.e. 1385 adducts in
108 nt) was predicted for estragole dose levels of 54 and 107 mg/
kg bw/day respectively. Table 2 also shows the predicted PBK model
outcomes for the formation of estragole DNA-adducts following an
exposure to 54 and 107 mg/kg bw/day estragole in the presence of
nevadensin at levels reﬂecting the ratio between estragole and
nevadensin in PSF2. Results reveal that, at 54 and 107 mg/kg bw/
day estragole, the reduction of E-30-N2-dGuo DNA-adduct forma-
tion is predicted by the PBK model to equal 89% and 88% following
the co-administration of estragole and nevadensin at a ratio rele-
vant for their occurrence in PFS2. Extracts of PFS consisting of basil
essential oils were able to inhibit SULT activity only to a moderate
extent and the effect of this SULT-inhibition was not further inves-
tigated. It should be noted that the rodent bioassay by Miller et al.
(1983) was performed using dose levels of estragole that consider-
ably exceed the levels of exposure to estragole resulting from the
use of basil-containing PFS. The levels of DNA-adduct formationTable 2
Overview of the PBK-predicted formation of estragole DNA-adducts in rat liver in the pres
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107 127 4114at levels of 4.6 and 13.9 lg/kg bw/day estragole, the estimated dai-
ly intake of estragole resulting from the use of PFS1 at the recom-
mended daily intake of 1 or 3 capsules respectively, were predicted
by the PBK model to equal 0.1 adducts per 108 nt or 0.3 adducts per
108 nt. Co-administration of estragole and nevadensin, at a dose
reﬂecting their actual levels in PFS1, was predicted to result in a
decrease of estragole DNA-adduct formation by 0.02% and 0.07%
following exposure to 4.6 or 13.9 lg/kg bw/day estragole respec-
tively. For PFS2, DNA-adduct formation was predicted by the PBK
model to amount to 0.1 adducts in 108 nt or 0.2 adducts in 108 nt
following exposure to 5.4 or 8.1 lg/kg bw/day estragole respec-
tively, the estimated daily intake of estragole resulting from the
use of PFS2 at the recommended daily intake of 4 and 6 capsules
respectively. The formation of estragole DNA-adducts was pre-
dicted to decrease by 0.22% and 0.33% at estragole intake levels
of 5.4 and 8.1 lg/kg bw/day in the presence of nevadensin at a dose
reﬂecting their actual levels in PFS2 amounting to 6.4 or 9.6 lg/
kg bw/day nevadensin respectively. These results demonstrate that
the consequences of the in vivo matrix-derived combination effect
are especially observed in rodent bioassays at estragole dose levels
that cause signiﬁcant cancer incidences but are predicted to be
limited at exposure levels of estragole and nevadensin relevant
for the daily use of PFS consisting of powdered basil material. For
the extracts consisting of basil essential oil only the PBK predicted
levels of DNA-adducts formed upon intake of estragole at dose lev-
els resulting from intake of PSF3, PSF4 and PSF5 at the recom-
mended daily dose levels were calculated and were found to
amount to 128, 3–13 and 55–87 in 108 nt respectively.3.4. BMDL10 analysis and updated risk assessment using the MOE
approach
Table 3 presents a summary of the incidence of hepatocellular
carcinomas as observed in a long term carcinogenicity study in
which rodents were exposed to estragole at dose levels of 54 or
107 mg/kg bw/day without the natural (botanical) matrix being
present (Miller et al., 1983). Based on the PBK model predictions
for the reduction in estragole DNA-adduct formation in rat liver
following the combined exposure to estragole and nevadensin (Ta-
ble 2), a reﬁnement of the incidences of hepatocellular carcinomas
as reported by Miller et al. (1983) was made assuming a propor-
tional reduction in DNA-adduct formation and hepatomas. Table 3
provides a summary of the reﬁned hepatoma incidences thus
obtained.
Based on the reﬁned hepatoma incidences obtained, a BMD
analysis was performed resulting in BMDL10 values ranging be-
tween 21–25 mg/kg bw/day and 63–87 mg/kg bw/day when using
the estragole to nevadensin ratios of PFS1 and PFS2 respectively
(Table 4) (for details on BMD analysis see Table S1 in the Supple-
mentary Materials). Subsequently, MOE values were calculated
by comparing the newly deﬁned BMDL10 values with the estimatedence or absence of nevadensin at a ratio of estragole and nevadensin reﬂecting their
ensin Adducts in 108 nt in the presence of nevadensin










Overview of the incidence of hepatomas in rodents following long-term exposure to
pure estragole (Miller et al., 1983) and the calculated incidence of hepatomas taking






























0 0 0/50 0 0/50
54 8 27/48 65 9/48
107 15 35/49 66 12/49
Basil-containing PFS2
0 0 0/50 0 0/50
54 64 27/48 89 3/48
107 127 35/49 88 4/49
a The data used to predict the reduction in DNA-adduct formation in rat liver
following the combined exposure to estragole and nevadensin are presented in
Table 2.
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ciﬁc basil-containing PFS (i.e. 0.005–0.014 mg estragole/kg bw/day
and 0.005–0.008 mg estragole/kg bw/day for PFS1 and PFS2
respectively). Table 4 shows the reﬁned MOE values that were ob-
tained in this way. For PFS1 the reﬁned MOE values vary between
2000 and 5000 and for PFS2 MOE values were found to amount to
8000–20,000 (Table 4). These reﬁned MOE values are considerably
higher than the MOE values of 200–1000 and 400–1000 that were
previously derived using the non-reﬁned BMDL10 values from tu-
mour data obtained in a rodent study using puriﬁed estragole
without the natural (botanical) matrix being present (Miller
et al., 1983; van den Berg et al., 2011b).4. Discussion
In the presented paper, the consequences of combined exposure
to estragole and other compounds present in basil-containing PFS
on the SULT-mediated bioactivation of estragole were studied.
The results demonstrated that methanolic extracts of PFS consist-
ing of powdered basil material contain potent SULT inhibitors. In
line with these ﬁndings, a signiﬁcant inhibition of SULT activity
was previously also shown for a methanolic extract prepared from
basil as such (Alhusainy et al., 2010, 2012; Jeurissen et al., 2008). It
is important to note that results of the present study also revealed
that the level of SULT-inhibition by PFS prepared from the essential
oil of basil was markedly lower than that of PFS consisting of
powdered basil material. In line with these ﬁndings, Müller et al.Table 4
Updated risk assessment based on the MOE approach taking into account the presence o
effect).
PFS Daily Intake Estragole
(mg/kg bw/day)a
(van den Berg et al., 2011b)
MOE using data from
Miller et al. (1983)






Details on BMD analysis can be found in Table S1 in the Supplementary Materials.
a Using the dose of PFS intake as recommended by the manufacturer of the basil-conta
estimates of estragole were obtained assuming a body weight of 60 kg.
b Reﬁned MOE = reﬁned BMDL10 (mg/kg bw/day)/daily intake estragole (mg/kg bw/da
c ND: Not Determined.(1994) reported that basil essential oil, containing 88% estragole,
was found to induce unscheduled DNA Synthesis (UDS) in the same
concentration range as pure estragole showing that there was no
protective effect of the remaining compounds present in the essen-
tial oil. The differences between the observed protective effects of
PFS consisting of powdered basil material and PFS consisting of ba-
sil essential oils can be explained by the fact that PFS consisting of
powdered basil material contain other compounds in addition to
estragole that exert a substantial SULT-inhibiting activity whereas
the presence of such modulating compounds in PFS consisting of
basil essential oil is apparently limited. Thus, assessing the risk
to human health resulting from the use of basil-containing PFS,
one should take into account the speciﬁc processing and manufac-
turing conditions used since differences in these production pro-
cesses can induce marked changes in composition, especially
when extracting essential oils containing concentrated levels of
individual (toxic) ingredients such as estragole.
In the present study, the ﬂavonoids nevadensin and apigenin
were identiﬁed in the methanolic extracts of PFS consisting of
powdered basil material as the compounds responsible for inhibit-
ing SULT activity. In line with these ﬁndings, both ﬂavonoids were
previously identiﬁed as the major SULT-inhibiting constituents in
methanolic extracts of intact basil sold in the supermarket for
use as a herb (Alhusainy et al., 2010, 2012). Other ﬂavonoids that
are reported to be present in some basil varieties have also been
demonstrated to exert SULT-inhibiting activities (Alhusainy et al.,
2012). These ﬂavonoids include luteolin and catechin. However,
it is important to realise that according to literature, nevadensin
is one of the major ﬂavonoids of basil and exists in almost all vari-
eties of the genus Ocimum basilicum L. whereas apigenin, luteolin
and catechin are present in relatively low quantities or are only
present in some basil varieties (Grayer et al., 1996, 2004; Shan
et al., 2005). For example, the level of apigenin in different varieties
of the genus O. basilicum L. was estimated to be up to 71-fold lower
compared to the level of nevadensin found in the same basil leaf
sample (Grayer et al., 2004). In addition, the Ki value for SULT-inhi-
bition by apigenin was shown to be 175-fold higher than the Ki va-
lue for SULT-inhibition by nevadensin (i.e. 4 nM) (Alhusainy et al.,
2010, 2012) corroborating nevadensin to be a more important
SULT inhibitor. Based on these results, the effect of apigenin on
SULT-mediated bioactivation of estragole can be expected to be
signiﬁcantly lower than that of nevadensin. Furthermore, nevaden-
sin was not only demonstrated to be a potent inhibitor of SULT
activity in vitro, but it was recently also shown to signiﬁcantly in-
hibit the SULT-mediated bioactivation and DNA-adduct formation
of estragole in vivo (Alhusainy et al., 2013).
Since nevadensin can markedly reduce estragole DNA-adduct
formation in vivo (Alhusainy et al., 2013), the adverse effects of
estragole are likely to be lower when estragole is consumed in a
matrix of basil-containing PFS compared to studies administeringf the SULT inhibitor nevadensin in basil-containing PFS (matrix-derived combination
Reﬁned BMDL10 taking into account
the matrix-derived combination
effect (mg/kg bw/day)








ining PFS and the chemically determined levels of estragole in the PFS, daily intake
y).
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taining PFS as described previously (van den Berg et al., 2011b),
by using the BMDL10 data obtained from a rodent study with high
dose levels of the pure estragole (Miller et al., 1983), may result in
an overestimation of the priority for risk management and the po-
tential risk for human health. Therefore, an updated risk assess-
ment of basil-containing PFS using the MOE approach was made
in the present study. To this end, studies in rodents should ideally
be performed with the botanical or the botanical preparation of
interest, allowing the calculation of speciﬁc BMDL10 values. How-
ever, obviously, performing rodent bioassays for all basil-contain-
ing PFS is practically unfeasible as the generation of such data is
expensive, labour-intensive and above all requires extensive ani-
mal testing. Therefore, the present study focused on the chemical
identiﬁcation of the most potent SULT inhibitor in basil-containing
PFS and the use of the previously developed and validated
estragole–nevadensin PBK model (Alhusainy et al., 2013) to predict
the possible in vivo reduction in estragole DNA-adduct formation,
taking for each PFS the relative ratio between its levels of estragole
and nevadensin into account. To obtain this reﬁned estimate, the
possible reduction in the values for the incidence of hepatocellular
carcinomas reported by Miller et al. (1983) was predicted using the
PBK model, subsequently allowing the calculation of reﬁned
BMDL10 data. Based on this approach, MOE values could be calcu-
lated for the individual PFS. These MOE values were found to be
considerably higher than the MOE values that were previously cal-
culated not taking the matrix-derived combination effect into ac-
count by using the non-reﬁned BMDL10 values (van den Berg
et al., 2011b). The results now presented indicate a lower priority
for risk management actions for the powdered basil-containing
PFS when considering the consequences of the botanical matrix
on the bioactivation of estragole. These results indicate that for
these PFS the use of BMDL10 data derived from long-term carcino-
genicity studies using pure estragole results in an overestimation
of the potential risk for human health. In contrast, it was concluded
that the matrix-derived combination effect of PFS consisting of ba-
sil essential oil is only of minor importance suggesting that the use
of BMDL10 data from studies using pure estragole accurately re-
ﬂects the potential risk for human health resulting from the use
of these PFS.
It should be noted that the estragole doses tested by Miller et al.
(1983) are not representative for the human situation, since these
are dose levels high enough to cause detectable tumor incidences
in groups of 50 experimental animals. Risk assessment by the
MOE approach is done using rodent tumor data and is thus based
on dose levels actually inducing a signiﬁcant tumor incidence
and not necessarily on realistic human intake levels. At these high
dose levels used in the Miller et al. study the concomitant dose of
nevadensin is also high and apparently high enough to reach neva-
densin levels in the liver that are in the range of the Ki value of
4 nM for SULT-inhibition (Alhusainy et al., 2010). The presented
study however also gives an estimate of the effects at estragole
and nevadensin dose levels representing a realtistic human intake.
The matrix-derived combination effect of nevadensin on the bioac-
tivation of estragole was predicted to be limited at dose levels of
estragole and nevadensin relevant for the use of PFS consisting of
powdered basil-material. At these dose levels the corresponding
dose of nevadensin is not high enough to reach the Ki of nevaden-
sin in vivo. This illustrates that testing compounds in the presence
of their natural matrix in rodent bioassays may not necessarily
provide better BMDL10 values for risk assessment, and that the
importance of a matrix-derived combination effect for risk assess-
ment of individual compounds should be done on a case-by-case
basis also taking into account analysis of dose-dependent effects
on the interactions detected. On the basis of the results now avail-
able and our previous results showing MOE values rangingbetween 200–1000 and 1–40 for PFS consisting of powdered basil
material or its essential oil, respectively (van den Berg et al.,
2011b), it is still concluded that the use ofsome basil-containing
PFS is of priority for risk management actions and a potential risk
for human health.
In conclusion, compounds present in especially powdered basil-
containing PFS can modulate the bioactivation of estragole,
whereas this effect was limited for PFS consisting of basil essential
oil suggesting that the matrix-derived combination effect for basil-
containing PFS should be judged on a case-by-case basis. Further-
more, the present study provides an example of how PBK modeling
can be used in the risk assessment of botanicals and botanical
preparations, contributing to further reduction in the use of exper-
imental animals.
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